Intervacc is trading 3% down today at €0.10, with no fresh company-specific catalysts visible in the latest news flow.
- Recent disclosures regarding the March 2026 interim report and the AGM-approved long-term incentive program are not newly released and unlikely to drive today's price action.
- The decline likely reflects typical volatility inherent in small-cap, loss-making biotech stocks rather than a specific fundamental development.